ArchiMed acquires Eurolyser and Eurolab

ArchiMed used its Med II fund, which closed on €315m in 2017. The fund invests €5-50m in healthcare companies. This acquisition is the fund's fourth portfolio company and the firm's third in DACH.

A spokesperson for ArchiMed told Unquote: "ArchiMed convinced the company's management to engage thanks to the firm's veterinary and in vitro diagnostics experience."

The transaction is part of a succession agreement that will see a co-founder of Eurolyser retire. The company's co-CEO, Michael Gruber, will continue to manage the company, and the management team has reinvested in the transaction.

The firm plans to expand the company both through organic and inorganic measures. Dirk Ehlers and Michael Rasche, who are members of ArchiMed's MedTalent network of industry executives, have joined the Eurolyser board.

Debt was provided for the acquisition by an Austrian bank.

Eurolyser's revenues and profits are growing 10% annually, according to a statement.

Company
Eurolyser designs and engineers point-of-care testing devices and kits sold in Europe, the US and Japan. Founded in 2005, the company is based in Salzburg.

People
ArchiMed – Vincent Guillaumot (partner).
Eurolyser – Michael Gruber (CEO); Dirk Ehlers; Michael Rasche (board members).

Advisers
Equity – Baker McKenzie (legal); Deloitte (financial due diligence, tax); Candesic (commercial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• healthcare
• Archimed
• Deloitte
• Austria